Jerszyńska Paulina, Szultka-Młyńska Małgorzata
Department of Environmental Chemistry and Bioanalytics, Faculty of Chemistry, Nicolaus Copernicus University, Torun, Poland.
Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Torun, Poland.
Front Pharmacol. 2025 Aug 28;16:1637852. doi: 10.3389/fphar.2025.1637852. eCollection 2025.
Psychotropic drugs strongly affect the human psyche through their ability to modulate the neurotransmitter activity and to treat mental disorders and diseases. Monitoring of psychotropic drugs in clinical studies is significant. Thus. establishing methodologies for analyzing these drugs and their pharmacologically active metabolites in biological matrices is essential for patients' safety. Therefore, therapeutic drug monitoring (TDM) of these drugs in patients receiving pharmacotherapy in psychiatric hospitals is necessary to avoid medical complications, psychiatric adverse effects, or poisoning. In addition to TDM, the main factor in pharmacokinetics that should be monitored along with the drug is its metabolic pathway. The literature on transformation products (TPs) resulting from the psychotropic drug degradation is limited. Hence, to investigate the potential TPs of target compounds, electrochemistry (EC) and liver microsome assays were used to generate TPs, which were further characterized using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The results obtained by EC-(LC)-MS and liver microsome assays were compared with conventional studies by analyzing biological samples (human plasma) from patients.
The electrochemical mimicry of the oxidative phase I and II metabolism was achieved in a thin-layer cell equipped with a boron-doped diamond (BDD) working electrode under controlled potential conditions. Structures were proposed for the electrochemically generated products based on the MS/MS experiments. Moreover, in order to examine the proposed metabolic pathways of target compounds, the incubation with human liver microsomes was applied. Additionally, a sensitive, specific, and rapid LC-MS/MS method was developed and validated to quantify selected drugs and their metabolites in biological samples. The preparation of biological samples was accomplished through microextraction by a packed sorbent (MEPS). Finally, the results from LC-MS/MS analysis of biological samples, liver microsomes and electrochemical TPs were compared to evaluate the quality of electrochemical metabolism mimicry.
Data from experiments agreed with the data from electrochemical oxidation, which predicted some of the potential metabolites found in the human liver microsomes. EC-(LC)-MS is well-suited for the simulation of the oxidative metabolism of selected psychotropic drugs and acts as the orthogonal source of information about drug metabolites compared to liver microsomes and biological matrices. EC-(LC)-MS enables the direct identification of reactive TPs, circumvents time-consuming sample preparation and is ethically advantageous because it reduces the need for animal experiments.
精神药物通过调节神经递质活性以及治疗精神障碍和疾病,对人类心理产生强烈影响。在临床研究中监测精神药物具有重要意义。因此,建立分析生物基质中这些药物及其药理活性代谢物的方法对于患者安全至关重要。所以,对精神病医院接受药物治疗的患者进行这些药物的治疗药物监测(TDM),以避免医疗并发症、精神不良反应或中毒是必要的。除了TDM,药代动力学中与药物一起应监测的主要因素是其代谢途径。关于精神药物降解产生的转化产物(TPs)的文献有限。因此,为了研究目标化合物的潜在TPs,采用电化学(EC)和肝微粒体试验来生成TPs,并使用液相色谱 - 串联质谱(LC - MS/MS)对其进行进一步表征。通过分析患者的生物样品(人血浆),将EC - (LC) - MS和肝微粒体试验获得的结果与传统研究进行比较。
在配备硼掺杂金刚石(BDD)工作电极的薄层电池中,在可控电位条件下实现氧化I相和II相代谢的电化学模拟。基于MS/MS实验为电化学产生的产物提出结构。此外,为了研究目标化合物的拟议代谢途径,采用与人肝微粒体孵育的方法。另外,开发并验证了一种灵敏、特异且快速的LC - MS/MS方法,用于定量生物样品中选定的药物及其代谢物。生物样品的制备通过填充吸附剂微萃取(MEPS)完成。最后,比较生物样品、肝微粒体和电化学TPs的LC - MS/MS分析结果,以评估电化学代谢模拟的质量。
实验数据与电化学氧化数据一致,电化学氧化预测了在人肝微粒体中发现的一些潜在代谢物。EC - (LC) - MS非常适合模拟选定精神药物的氧化代谢,并且与肝微粒体和生物基质相比,是关于药物代谢物的正交信息来源。EC - (LC) - MS能够直接鉴定反应性TPs,避免了耗时的样品制备,并且在伦理上具有优势,因为它减少了动物实验的需求。